Analyst Price Target is $380.00
▲ +17.63% Upside Potential
This price target is based on 11 analysts offering 12 month price targets for Medpace in the last 3 months. The average price target is $380.00, with a high forecast of $435.00 and a low forecast of $336.00. The average price target represents a 17.63% upside from the last price of $323.04.
Current Consensus is
Hold
The current consensus among 11 contributing investment analysts is to hold stock in Medpace. This Hold consensus rating has held steady for over two years.
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, the company offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.
Read More